Skip to main content

Building

A better future

through education, skill development and research

LEARN MORE

Cannabis-Based Compound May Reduce Seizures in Children with Epilepsy

Interest has been growing in the use of cannabinoids—the active chemicals in cannabis or marijuana— for the treatment of epilepsy in children. A recent Epilepsia analysis of relevant published studies indicates that this strategy looks promising.

Wednesday, December 5, 2018 12:01 am EST
"Research in this area is active, and we expect a dramatic increase in the number of studies over the next few years."

Interest has been growing in the use of cannabinoids—the active chemicals in cannabis or marijuana— for the treatment of epilepsy in children. A recent Epilepsia analysis of relevant published studies indicates that this strategy looks promising.

The analysis included four randomized controlled trials and 19 non-randomized studies, primarily involving cannabidiol, a particular type of cannabinoid that does not have psychoactive effects.

Among randomized controlled trials involving children with severe forms of epilepsy, there was no statistically significant difference between cannabidiol and placebo in terms of freedom from seizures, sleep disruption, or vomiting. There was a statistically significant reduction in the median frequency of monthly seizures with cannabidiol compared with placebo and an increase in number of participants with at least a 50 percent reduction in seizures.

”Although we saw no significant difference in the number of children who became completely seizure free, we that found a significant number of these children achieved a 50 percent or more reduction in seizures. Any reduction in seizures has a striking impact on the lives of these children and their families,“ said lead author Jesse Elliott, of the University of Ottawa, in Canada. ”Research in this area is active, and we expect a dramatic increase in the number of studies over the next few years.“

Additional Information

Link to Study:  https://onlinelibrary.wiley.com/doi/full/10.1111/epi.14608

About Journal

Epilepsia is the leading, most authoritative source for current clinical and research results on all aspects of epilepsy. As the journal of the International League Against Epilepsy, subscribers every month will review scientific evidence and clinical methodology in:

  • clinical neurology,
  • neurophysiology,
  • molecular biology,
  • neuroimaging,
  • neurochemistry,
  • neurosurgery,
  • pharmacology,
  • neuroepidemiology,
  • therapeutic trials.

In each issue subscribers will find original peer reviewed articles, brief communications, editorial commentaries, meeting reports, and announcements.

About Wiley

Wiley is a global leader in research and education. Our online scientific, technical, medical, and scholarly journals, and our digital learning, assessment, certification and student-lifecycle services and solutions help universities, academic societies, businesses, governments and individuals to achieve their academic and professional goals. For more than 200 years, we have delivered consistent performance to our stakeholders. The Company's website can be accessed at www.wiley.com.


Multimedia Files:

Preview image

Contact:

Penny Smith
+44 (0) 1243 770448
newsroom@wiley.com

Tags:

Business Wire NewsHQsm